• Chemicals ProductsAmino Acid Organic Raw Materials Inorganic Salt Cosmetic Raw Materials Daily Chemicals
  • Raw Materials PowderHuman APIs Vertinary Drug Plant Extract Pharmaceutical Intermediate Pharmaceutical Raw Materials
  • OEM & ODMCapsule Softgel Capsule Gummies Drop & drinks Tables
  • Feed & Food AdditivesPlant Growth Regulator Feed Additives Food Additives Nutrition Enhancers Vitamins
  • Sunitinib Malate powder Raw Materials CAS 341031-54-7

    • Sunitinib Malate powder Raw Materials CAS 341031-54-7
    • Sunitinib Malate powder Raw Materials CAS 341031-54-7
    • Sunitinib Malate powder Raw Materials CAS 341031-54-7
    • Sunitinib Malate powder Raw Materials CAS 341031-54-7 workshop
    • Sunitinib Malate powder Raw Materials CAS 341031-54-7 factory
    • Sunitinib Malate powder Raw Materials CAS 341031-54-7

    Product Overview:

    Sunitinib Malate powder is a new oral multi-target anti-tumor drug, belonging to the multi-target tyrosine kinase inhibitor, the product name suntent, which was successfully developed by Pfizer in the United States. Sunitinib Malate has dual anti-tumor effects. Sunitinib Malate is the only drug to break through the 2-year survival of advanced kidney cancer, and has a core position in the treatment of renal cell carcinoma and gastrointestinal stromal tumor. It was launched in the United States in February 2006. Sunitinib Malate is the first anti-cancer drug approved by the United States FDA to treat two diseases at the same time.

    Sunitinib Malate powder Raw Materials CAS 341031-54-7 Attributes

    CAS:341031-54-7

    MF:C26H33FN4O7
    Sunitinib Malate powder

    MW:532.57

    EINECS:638-825-9

    Specification:Sunitinib Malate powder

    Sample:Sunitinib Malate powder

    Brand:Sunitinib Malate powder

    Appearance: powder

    Storage: Cool Dry Place

    Brand: chemical Raw Materials

    Shelf Life: 2 Years

    Test Method: HPLC

    Sunitinib Malate powder Raw Materials CAS 341031-54-7 Details

    Uses and synthesis of Sunitinib Malate powder

    Sunitinib Malate powder is a new oral multi-target anti-tumor drug, belonging to the multi-target tyrosine kinase inhibitor, the product name suntent, which was successfully developed by Pfizer in the United States. Sunitinib Malate has dual anti-tumor effects. Sunitinib Malate is the only drug to break through the 2-year survival of advanced kidney cancer, and has a core position in the treatment of renal cell carcinoma and gastrointestinal stromal tumor. It was launched in the United States in February 2006. Sunitinib Malate is the first anti-cancer drug approved by the United States FDA to treat two diseases at the same time.

    Sunitinib Malate powder

    Applications/Functions of Sunitinib Malate powder

    Sunitinib Malate powder is the first novel targeted drug that can selectively target multiple tyrosine kinase receptors, combining two mechanisms of action: anti-angiogenesis, which interrupts blood supply to tumor cells, and anti-tumor, which directly attacks tumor cells.

    Physicochemical Property of Sunitinib Malate powder

    Sunitinib Malate powder

    Our advantage
    Our Factory
    Shipping
    Tel: 86-17339854922
    WhatsApp: 8617339854922
    WeChat: 17339854922
    E-mail: sales20@interlgroup.com
    Add: Room 305 , 3/F , Haipai Decoration Office Building , Yudu Avenue , Yuncheng , Shanxi
    ©2024 Global Asap Nutrition Factory Co., Ltd.